In the Claims

This listing of claims will replace all prior versions and listings of claims in this application.

1 (Previously presented). A method for treating a condition selected from the group consisting of nausea, dizziness, blurred vision and emesis, wherein said method comprises administering, to a patient in need of such treatment, an effective amount of single enantiomer (+)-nefopam, and wherein the condition is induced by chemotherapy, surgery or motion.

2 - 3 (Cancelled).

- 4 (Previously presented). The method, according to claim 1, wherein the condition is induced by motion.
- 5 (Previously presented). The method, according to claim 1, wherein the condition is induced by surgery.
- 6 (Previously presented). The method, according to claim 5, wherein the condition is induced by chemotherapy.

7 (Cancelled).

- 8 (Previously presented). The method, according to claim1, wherein the patient is also administered another agent that has anti-emetic properties.
- 9 (Previously presented). The method, according to claim 8, wherein said agent is selected from the group consisting of phenothiazines, 5HT3 receptor antagonists, dopamine antagonists, anticholinergic agents, anti-histamines, histamines, cannabinoids, corticosteroids, GABA receptor antagonists, NK1 receptor antagonists, and α_2 and α_3 adrenoceptor antagonists.

Docket No. GJE-7147 Serial No. 10/517,881

10 (Previously presented). The method, according to claim 8, wherein said agent is selected from the group consisting of cyclizine, dolasetron, granisetron, andansetron, tropisetron, nabilone, scopolenine, cinnerizine, promethazine, betahistine, dexamethasone, methylpredrisolone, metoclopramide, chlorpromazine, perphenazine, prochlorperazine, thiethylperazine, droperidol, domperidone and haloperidol.

11 (Currently amended). A method for the treatment of a condition selected from the group consisting of nausea, dizziness, blurred vision and emesis, wherein said method comprises administering, to a patient in need of such treatment, an effective amount of single enantiomer (+)-nefopam, and wherein the condition is associated with dysmenorrhoea, migraine, cancer or other pain condition, wherein said method comprises administering, to a patient in need of such treatment, an effective amount of single enantiomer (+)-nefopam.